drugset / Trial / NCT01814917

Long-term Extension Study of MCI-196

NCT01814917

Phase 3 Terminated 6 enrolled Tanabe Pharma Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The Primary Objectives of this study are to assess the long-term efficacy of treatment with colestilan (MCI-196) (including combination therapy) and to assess the long-term safety of treatment with colestilan (MCI-196) (including combination therapy).

Timeline

Start
2013-08
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject COLESTILAN CHLORIDE Other / unclassified 3 g
Subject COLESTILAN CHLORIDE Other / unclassified 6 g
Subject COLESTILAN CHLORIDE Other / unclassified 9 g
Subject COLESTILAN CHLORIDE Other / unclassified 12 g
Subject COLESTILAN CHLORIDE Other / unclassified 15 g